Primary Mucosal Melanoma Masquerading as Nasal Polyp A Diagnostic Challenge
Nasal mucosal melanoma (MM) is a rare and aggressive tumor, first described by Lucke in 1869. It accounts for 0.5%–2% of all melanomas. Its incidence is more in fair skinned individuals, and most commonly seen in the mean age of 60 years with slight male predominance.
Targeted therapeutic strategies for melanoma
Melanoma accounts for a small proportion of skin cancers diagnosed each year, but it has a high degree of malignancy and rapid progression, resulting in a short survival period for patients. The incidence of melanoma continues to rise, and now melanoma accounts for 1.7% of cancer diagnoses worldwide and is the fifth most common cancer in the United States.
Risk of second primary lung cancer in patients with thyroid cancer: a meta-analysis based on big population studies
Previous studies have revealed that the number of cancer survivors developing a second primary malignancy is increasing, especially among thyroid cancer patients, and lung cancer is still the main cause of cancer death.
Bioinformatics identify the role of chordin-like 1 in thyroid cancer
Patients with slowly progressive and/or symptomatic oligometastatic radioactive iodine refractory (RAIR) differentiated thyroid carcinomas (DTCs) are candidates to receive locoregional treatment to delay the start of systemic therapy with multikinase inhibitors.
Intratumoral heterogeneity contributes to the chemotherapy prognosis of breast cancer
Previous studies have shown that intratumoral heterogeneity (ITH) is associated with poor clinical outcomes and is thought to be a mechanism of resistance to chemotherapy and radiotherapy.
A review of the neurological complications of breast cancer
Conducting broad assessments of the main burden of breast cancer is the core factor for improving overdiagnosis and overtreatment of breast cancer patients as well as their survival rates. Breast cancer patients may experience neurological complications that cause devastating effects on them.
